Date: 2017-07-25
Type of information: Nomination
Compound: chief medical officer
Company: Abeona Therapeutics (USA - NY)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 25, 2017, Abeona Therapeutics announced that Juan Ruiz has joined the company as chief medical officer. He will be responsible for leading all clinical development, medical affairs and related functions and will report directly to Timothy J. Miller, Ph.D., President and CEO.
- Dr. Juan Ruiz is well regarded for his extensive research in molecular biology and gene therapy. He has previously held global leadership positions at Lykera Biomed and Digna Biotech, where he spent over 13 years leading teams dedicated to developing gene therapy translational medicine programs. During his tenure as Chief Medical Officer of Digna Biotech, Dr. Ruiz’s proven track record demonstrated a “start to finish” scope, from proof-of-concept studies and regulatory IND and IMPD submissions, to manufacturing, clinical trial design and execution, and partnering and licensing activities. In addition, he has expertise in the manufacturing and quality control of the adenoviral vectors that were tested in his clinical trials.
- Dr. Ruiz has been instrumental in designing Patient Reported Outcomes (PRO) in the USA to assess skin outcome measures in patients with Systemic Sclerosis for use as primary endpoints in Phase IIb trials. Additional work includes multiple regulatory designation achievements and successful Scientific Advice and Protocol Assistance meetings with the FDA and EMA. He is the author of over forty peer-reviewed journal articles and book chapters and an inventor on multiple issued patents. Dr. Ruiz holds a M.D. with a specialty in Hepatology and a Ph.D. in Molecular Biology, both from the University of Navarra, and completed his post-doctoral fellowship at the University of Connecticut. He holds a MBA from IESE Business School, also at the University of Navarra.
Financial terms:
Latest news:
Is general: Yes
